Janux Therapeutics, Inc.
NASDAQJanux Therapeutics reports after the bell today with short sellers meaningfully pulling back, even as the analyst community has spent months slashing price targets. The short interest story is the most notable shift in positioning. Bears have covered aggressively — short interest has dropped nearly 18% over the past month to roughly 10.6% of the float, down from around 13% in late…
Snapshot as of 7 Aug 2026
Janux Therapeutics reports after the bell today with short sellers meaningfully pulling back, even as the analyst community has spent months slashing price targets. The short interest story is the most notable shift in…
Janux Therapeutics heads into its May 8 Q1 print under a cloud of analyst capitulation that has reset price expectations dramatically lower — yet a still-sizeable short position and defensive options skew suggest…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for JANX — free to start on ORTEX.
Sign up for free →Open JANX on ORTEX